

Ref: FOI/GS/ID 9049

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

24 April 2024

### **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Biliary Tract and Non-Small Cell Lung Cancer Treatment.

*You asked: All questions are shown as received by the Trust.  
I would be grateful if you could please provide the following information with regards to patients treated with Durvalumab (Imfinzi) and Nivolumab.*

*Where the specified Nov 23 – March 24 timeframe is not possible to provide, could you please provide the latest 5 months of data you have, and specify which timeframe this covers.*

1. *How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?*
  - A) *Biliary Tract Cancer*
  - B) *Non-Small Cell Lung Cancer*
2. *How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Nivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).*
3. *How many unique total patients were treated last month (March 24) with Durvalumab for the following indications?*
  - C) *Biliary Tract Cancer*
  - D) *Non-Small Cell Lung Cancer*
4. *How many patients received their first treatment in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?*
  - E) *Biliary Tract Cancer*
  - F) *Non-Small Cell Lung Cancer*

Trust response:

1.
  - A) Biliary Tract Cancer 0
  - B) Non-Small Cell Lung Cancer 2
  
2. Answer=1
  
3.
  - C) Biliary Tract Cancer 0
  - D) Non-Small Cell Lung Cancer 1
  
4.
  - E) Biliary Tract Cancer 0
  - F) Non-Small Cell Lung Cancer 1